Prognostic value and therapeutic efficacy of interstitial circulating tumor cells in patients with advanced gastric cancer

Table 3 Results of univariate analysis affecting the prognosis of patients with advanced gastric cancer

Prognostic factors	HR	95%CI	P value
Gender, male vs female	0.975	0.271-0.501	0.969
Age, < 60 years vs ≥ 60 years	2.427	0.859-6.851	0.094
Degree of differentiation, well vs poor	4.076	1.291-12.863	0.017
TNM staging, I-II vs III	1.041	0.365-2.968	0.941
Infiltration depth, T1-T2 vs T3-T4	3.676	0.821-16.462	0.089
Lymph node metastasis, N0-1 vs N2-3	1.020	0.357-2.912	0.970
I-CTCs, negative vs positive	17.158	2.227-132.196	0.006
CEA, < 5 vs ≥ 5	1.732	0.531-5.646	0.362
CA125, < 35 vs ≥ 35	0.041	0-66.291	0.397
CA19-9, < 37 vs ≥ 37	0.348	0.045-2.663	0.309
CA72-4, < 10 vs ≥ 10	0.936	0.208-4.205	0.931

I-CTCs: Interstitial circulating tumor cells; TNM: Tumor-node-metastasis; CEA: Carcinoembryonic antigen; CA: Carbohydrate antigen.